Half-life

113 h

Tmax

48 h

Category

glp1

Dulaglutide is a once-weekly GLP-1 receptor agonist engineered as an Fc-fusion protein. By fusing a GLP-1 analogue to a modified IgG4 Fc fragment, the molecule exploits the neonatal Fc receptor (FcRn) recycling pathway to achieve a half-life of approximately 120 hours. It is marketed as Trulicity for type 2 diabetes. Compared with other once-weekly GLP-1 RAs, dulaglutide has a distinct dosing pen and titration schedule. Patients tracking their therapy in a log app can benefit from recording dose timing, injection site rotation, and gastrointestinal side effects to identify personal tolerance patterns.

Mechanism

A long-acting GLP-1 receptor agonist in which the GLP-1 peptide is fused to an antibody Fc fragment, extending its half-life to allow once-weekly dosing. Like other GLP-1 agonists it is associated with glucose-dependent insulin secretion, slowed gastric emptying, and reduced appetite.

Research summary

Approved for type 2 diabetes and studied in the AWARD program, including a cardiovascular outcomes trial (REWIND). Marketed as Trulicity.

Reported side effects

Gastrointestinal effects (nausea, diarrhea, vomiting) are most commonly reported. Prescribing information includes warnings such as thyroid C-cell tumor risk in rodents and pancreatitis. This is not a complete safety profile.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

AWARD program and REWIND cardiovascular outcomes trial · peer-reviewed clinical trials (e.g. The Lancet) (2019)search PubMed for dulaglutide REWIND
Trulicity prescribing information · FDA prescribing information (2014)available via DailyMed / accessdata.fda.gov

References

Dulaglutide clinical pharmacokineticsDOI: 10.1007/s40262-016-0421-4

TrackPep — це трекер. Він зберігає те, що ви вносите, і ніколи не рекомендує та не розраховує кількість препарату.